Cerecor Inc
2400 Boston Street
Suite 324
Baltimore
Maryland
21224
United States
Tel: 410-522-8707
Website: http://www.cerecor.com/
About Cerecor Inc
107 articles about Cerecor Inc
-
Cerecor Inc. To Present At The 15th Annual BIO Investor Forum In San Francisco On October 18th, 2016
10/10/2016
-
Cerecor Inc. Announces Acquisition Of TARP-G8-AMPA Receptor Antagonist (CERC-611) From Eli Lilly
9/26/2016
-
Cerecor Inc. Announces Completion Of Enrollment In Phase II Clinical Trial With CERC-301 As An Oral, Adjunctive Treatment Of Major Depressive Disorder
9/21/2016
-
Cerecor Inc. Enters Into A $15 Million Common Stock Purchase Agreement With Aspire Capital Fund
9/12/2016
-
Cerecor Inc. Announces Last Patient Enrolled In Phase II Clinical Trial With CERC-501 For Smoking Cessation
9/6/2016
-
Cerecor Inc. To Present At 23rd Annual Newsmakers In The Biotech Industry Conference In New York City, September 9, 2016
9/1/2016
-
Cerecor Inc. Announces Initiation Of Second CERC-501 Phase II Clinical Trial In Smokers
8/29/2016
-
Cerecor Inc. To Present At The 18th Annual Rodman & Renshaw Global Investment Conference In New York City September 11-13th, 2016
8/22/2016
-
Cerecor Inc. Reports Second Quarter 2016 Financial Results
8/15/2016
-
Cerecor Inc. Announces Research Grant From The Department Of Defense To Study CERC-501 In Animal Models For Co-Morbid Post-Traumatic Stress Disorder And Alcohol Use Disorder
7/25/2016
-
Cerecor Inc. Announces $1 Million Research & Development Grant From The National Institute On Alcohol Abuse And Alcoholism At The NIH
7/20/2016
-
Cerecor Inc. Reports First Quarter 2016 Financial Results
5/16/2016
-
Cerecor Inc. Announces $1.0 Million Research & Development Grant From The National Institute on Drug Abuse (NIDA) At The NIH
4/11/2016
-
Cerecor Inc. Reports Financial Results for the Fourth Quarter And Year Ended December 31, 2015
3/23/2016
-
Cerecor Inc. To Present At The Roth Conference On March 16th
3/8/2016
-
Cerecor Inc. To Host R&D Day In New York City On March 1, 2016
2/22/2016
-
Cerecor Inc. Announces Initiation Of Phase II Clinical Trial With CERC-501 For Smoking Cessation
2/2/2016
-
Cerecor Inc. To Present At The BIO CEO & Investor Conference In New York City
2/1/2016
-
Cerecor Inc. Announces Publication Describing Antidepressant Activity Of CERC-301 In Preclinical Model
1/19/2016
-
Cerecor Inc. Appoints Thomas Aasen To Board Of Directors
1/12/2016